

Janneke Pc Grutters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3630632/publications.pdf>

Version: 2024-02-01

101
papers

3,220
citations

159585

30
h-index

168389

53
g-index

105
all docs

105
docs citations

105
times ranked

5451
citing authors

#	ARTICLE	IF	CITATIONS
1	Robot-assisted Versus Open Radical Cystectomy in Bladder Cancer: An Economic Evaluation Alongside a Multicentre Comparative Effectiveness Study. <i>European Urology Focus</i> , 2022, 8, 739-747.	3.1	6
2	Methods for Early Assessment of the Societal Value of Health Technologies: A Scoping Review and Proposal for Classification. <i>Value in Health</i> , 2022, 25, 1227-1234.	0.3	4
3	Development of a decision analytical framework to prioritise operating room capacity: lessons learnt from an empirical example on delayed elective surgeries during the COVID-19 pandemic in a hospital in the Netherlands. <i>BMJ Open</i> , 2022, 12, e054110.	1.9	11
4	How can robot-assisted surgery provide value for money?. <i>BMJ Surgery, Interventions, and Health Technologies</i> , 2021, 3, e000042.	0.9	6
5	Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for) <i>Tj ETQq</i> 1.7 0.784314 rgBT	0.3	4
6	Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study. <i>European Urology</i> , 2021, 79, 609-618.	1.9	32
7	The Use of Decision Analytic Modeling in the Evaluation of Surgical Innovations: A Scoping Review. <i>Value in Health</i> , 2021, 24, 884-900.	0.3	3
8	State of the ART? Two New Tools for Risk Communication in Health Technology Assessments. <i>Pharmacoeconomics</i> , 2021, 39, 1185-1196.	3.3	4
9	Early health economic analysis of 1.5ÅT MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling. <i>Radiotherapy and Oncology</i> , 2021, 161, 74-82.	0.6	21
10	Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation. <i>Value in Health</i> , 2021, 24, 1126-1136.	0.3	4
11	Exploratory, Participatory and Iterative Assessment of Value: A Response to Recent Commentaries. <i>International Journal of Health Policy and Management</i> , 2021, 10, 42-44.	0.9	3
12	Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 967-974.	3.1	15
13	Development and Validation of the TRansparent Uncertainty ASsessment (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. <i>Pharmacoeconomics</i> , 2020, 38, 205-216.	3.3	23
14	The Potential Added Value of Novel Hearing Therapeutics: An Early Health Economic Model for Hearing Loss. <i>Otology and Neurotology</i> , 2020, 41, 1033-1041.	1.3	6
15	On the integration of early health technology assessment in the innovation process: reflections from five stakeholders. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 481-485.	0.5	12
16	Septoplasty versus non-surgical management for nasal obstruction in adults with a deviated septum: economic evaluation alongside a randomized controlled trial. <i>BMC Medicine</i> , 2020, 18, 101.	5.5	7
17	Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	13
18	A cost-effectiveness modeling study of robot-assisted (RARC) versus open radical cystectomy (ORC) for bladder cancer to inform future research. <i>European Urology Focus</i> , 2019, 5, 1058-1065.	3.1	20

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of the prevention of adhesions and adhesive small bowel obstruction after colorectal surgery with adhesion barriers: a modelling study. <i>World Journal of Emergency Surgery</i> , 2019, 14, 41.	5.0	12
20	Clinical biomarker innovation: when is it worthwhile?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1712-1720.	2.3	2
21	Exploring the risk-reward balance in focal therapy for prostate cancer—a contribution to the debate. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 382-384.	3.9	5
22	Early Assessment of Proof-of-Problem to Guide Health Innovation. <i>Value in Health</i> , 2019, 22, 601-606.	0.3	14
23	The potential health gain and cost savings of improving adherence in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1485-1492.	1.3	6
24	Mindfulness-Based Cognitive Therapy Versus Treatment as Usual in Adults with ADHD: a Trial-Based Economic Evaluation. <i>Mindfulness</i> , 2019, 10, 1803-1814.	2.8	2
25	In search of the most cost-effective monitoring strategy for vestibular schwannoma: A decision analytical modelling study. <i>Clinical Otolaryngology</i> , 2019, 44, 525-533.	1.2	8
26	Psychosomatic therapy for patients frequently attending primary care with medically unexplained symptoms, the CORPUS trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 697.	1.6	4
27	Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?. <i>Value in Health</i> , 2019, 22, 799-807.	0.3	14
28	Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling. <i>International Journal of Health Policy and Management</i> , 2019, 8, 575-582.	0.9	50
29	Potential savings in the diagnosis of vestibular schwannoma. <i>Clinical Otolaryngology</i> , 2018, 43, 285-290.	1.2	3
30	Value of Information Choices that Influence Estimates: A Systematic Review of Prevailing Considerations. <i>Medical Decision Making</i> , 2018, 38, 888-900.	2.4	10
31	Integrated prediction and decision models are valuable in informing personalized decision making. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 73-83.	5.0	10
32	Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study. <i>BMC Cancer</i> , 2018, 18, 861.	2.6	13
33	The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective. <i>PLoS ONE</i> , 2018, 13, e0197670.	2.5	78
34	Combining value of information analysis and ethical argumentation in decisions on participation of vulnerable patients in clinical research. <i>BMC Medical Ethics</i> , 2018, 19, 5.	2.4	4
35	THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 327-336.	0.5	1
36	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics—a decision analytical model. <i>BJU International</i> , 2017, 120, 659-665.	2.5	45

#	ARTICLE	IF	CITATIONS
37	A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. <i>Genetics in Medicine</i> , 2017, 19, 1055-1063.	2.4	220
38	Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes. <i>Value in Health</i> , 2017, 20, 256-260.	0.3	81
39	The merits of decision modelling in the earliest stages of the IDEAL framework: An innovative case in DIEP flap breast reconstructions. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 1696-1701.	1.0	9
40	Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 260.	1.7	4
41	HEADROOM BEYOND THE QUALITY- ADJUSTED LIFE-YEAR: THE CASE OF COMPLEX PEDIATRIC NEUROLOGY. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 5-10.	0.5	6
42	Real-life Data on Patient Characteristics, Cost and Effectiveness of Field-directed Treatment for Actinic Keratoses: An Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 346-350.	1.3	3
43	Quality of life after different procedures for regional control in oral cancer patients: cross-sectional survey. <i>Clinical Otolaryngology</i> , 2016, 41, 228-233.	1.2	26
44	Is the \$1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. <i>Clinical Chemistry</i> , 2016, 62, 1458-1464.	3.2	126
45	Parental quality of life in complex paediatric neurologic disorders of unknown aetiology. <i>European Journal of Paediatric Neurology</i> , 2016, 20, 723-731.	1.6	12
46	Intrathoracic versus Cervical ANastomosis after minimally invasive esophagectomy for esophageal cancer: study protocol of the ICAN randomized controlled trial. <i>Trials</i> , 2016, 17, 505.	1.6	37
47	Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. <i>Pharmacoeconomics</i> , 2016, 34, 315-322.	3.3	19
48	Societal and Economic Effect of Meniscus Scaffold Procedures for Irreparable Meniscus Injuries. <i>American Journal of Sports Medicine</i> , 2016, 44, 1724-1734.	4.2	10
49	A Next-Generation Framework: Deciding On The Role Of Costs In The Clinical Use Of Targeted Gene Panels, Exome And Genome Sequencing. <i>Value in Health</i> , 2015, 18, A352.	0.3	2
50	Network Meta-Analysis of Various Treatment Strategies in Resistant Hypertension. <i>Value in Health</i> , 2015, 18, A377.	0.3	3
51	Closing the information gap between clinical and postmarketing trials: the case of dabigatran: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 153-156.	3.0	7
52	Practice points in gynecardiology: Abnormal uterine bleeding in premenopausal women taking oral anticoagulant or antiplatelet therapy. <i>Maturitas</i> , 2015, 82, 355-359.	2.4	26
53	Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD). <i>BMC Psychiatry</i> , 2015, 15, 216.	2.6	20
54	Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy. <i>Pharmacoeconomics</i> , 2015, 33, 1-4.	3.3	32

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy. <i>Epilepsy Research</i> , 2015, 110, 119-131.	1.6	29
56	The diagnostic pathway in complex paediatric neurology: A cost analysis. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 233-239.	1.6	40
57	Surgical team composition has a major impact on effectiveness and costs in laparoscopic donor nephrectomy. <i>World Journal of Urology</i> , 2015, 33, 733-741.	2.2	11
58	Women's and healthcare professionals' preferences for prenatal testing: a discrete choice experiment. <i>Prenatal Diagnosis</i> , 2015, 35, 549-557.	2.3	38
59	The Authors'™ Reply: Comment on 'Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy'. <i>Pharmacoeconomics</i> , 2015, 33, 983-983.	3.3	3
60	Cost-effectiveness modelling in diagnostic imaging: a stepwise approach. <i>European Radiology</i> , 2015, 25, 3629-3637.	4.5	17
61	Yearly hypertension screening in women with a history of pre-eclampsia: a cost-effectiveness analysis. <i>Netherlands Heart Journal</i> , 2015, 23, 585-591.	0.8	5
62	Cost-effectiveness of selective neck dissection versus modified radical neck dissection for treating metastases in patients with oral cavity cancer: A modelling study. <i>Head and Neck</i> , 2015, 37, 1762-1768.	2.0	7
63	Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care. <i>Family Practice</i> , 2014, 31, 578-584.	1.9	18
64	Cost-Effectiveness of Early-Initiated Treatment for Advanced-Stage Epithelial Ovarian Cancer Patients: A Modeling Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 75-84.	2.5	4
65	Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>European Urology</i> , 2014, 66, 430-436.	1.9	171
66	The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 182, 53-61.	1.1	53
67	Reply to van der Wal, Alec Miners, and Jan van der Meulen's Letter to the Editor re: Maarten de Rooij, Simone Crienen, J. Alfred Witjes, Jelle O. Barentsz, Maroeska M. Rovers, Janneke P.C. Grutters. Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2013.12.012 . <i>European Urology</i> , 2014, 66, e30.	1.9	2
68	What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?. <i>Cancer Treatment Reviews</i> , 2014, 40, 60-67.	7.7	52
69	Cost-effectiveness of CTA, MRA and DSA in patients with non-traumatic subarachnoid haemorrhage. <i>Insights Into Imaging</i> , 2013, 4, 499-507.	3.4	21
70	How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines. <i>Value in Health</i> , 2013, 16, 855-862.	0.3	35
71	Acknowledging Patient Heterogeneity in Economic Evaluation. <i>Pharmacoeconomics</i> , 2013, 31, 111-123.	3.3	55
72	Value of Research and Value of Development in Early Assessments of New Medical Technologies. <i>Value in Health</i> , 2013, 16, 720-728.	0.3	20

#	ARTICLE	IF	CITATIONS
73	Protons in Head-and-Neck Cancer: Bridging the Gap of Evidence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1282-1288.	0.8	71
74	Management of the N0 neck in early stage oral squamous cell cancer: A modeling study of the cost-effectiveness. <i>Oral Oncology</i> , 2013, 49, 771-777.	1.5	59
75	Mindfulness-based cognitive therapy for patients with medically unexplained symptoms: A cost-effectiveness study. <i>Journal of Psychosomatic Research</i> , 2013, 74, 197-205.	2.6	41
76	Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2013, 31, 4283-4289.	1.6	35
77	Cost-Effectiveness of Hand-Assisted Retroperitoneoscopic Versus Standard Laparoscopic Donor Nephrectomy. <i>Transplantation</i> , 2013, 96, 170-175.	1.0	13
78	Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1295-1307.	1.1	16
79	Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it?. <i>Lancet Oncology</i> , The, 2012, 13, e169-e177.	10.7	78
80	The Role of the Expected Value of Individualized Care in Cost-Effectiveness Analyses and Decision Making. <i>Value in Health</i> , 2012, 15, 13-21.	0.3	25
81	Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions. <i>Value in Health</i> , 2011, 14, 777-784.	0.3	20
82	Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. <i>Cancer Treatment Reviews</i> , 2011, 37, 185-201.	7.7	86
83	Shared care for hearing complaints: guideline effects on patient flow. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 209-214.	1.8	0
84	The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. <i>Oral Oncology</i> , 2011, 47, 768-774.	1.5	94
85	When to Wait for More Evidence? Real Options Analysis in Proton Therapy. <i>Oncologist</i> , 2011, 16, 1752-1761.	3.7	29
86	Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review. <i>Oncologist</i> , 2010, 15, 93-103.	3.7	21
87	The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research. <i>Cancer Treatment Reviews</i> , 2010, 36, 468-476.	7.7	57
88	18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation. <i>European Journal of Cancer</i> , 2010, 46, 110-119.	2.8	46
89	Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. <i>Radiotherapy and Oncology</i> , 2010, 95, 32-40.	0.6	295
90	How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. <i>Radiotherapy and Oncology</i> , 2010, 95, 45-53.	0.6	166

#	ARTICLE	IF	CITATIONS
91	Health-related quality of life in patients surviving non-small cell lung cancer. <i>Thorax</i> , 2010, 65, 903-907.	5.6	77
92	Willingness to pay for a hearing aid: comparing the payment scale and open-ended question. <i>Journal of Evaluation in Clinical Practice</i> , 2009, 15, 91-96.	1.8	16
93	Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: A prospective study. <i>European Journal of Cancer</i> , 2009, 45, 588-595.	2.8	50
94	High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. <i>Radiotherapy and Oncology</i> , 2009, 91, 443-448.	0.6	42
95	Decision-Analytic Modeling to Assist Decision Making in Organizational Innovation: The Case of Shared Care in Hearing Aid Provision. <i>Health Services Research</i> , 2008, 43, 1662-1673.	2.0	7
96	Willingness to Accept versus Willingness to Pay in a Discrete Choice Experiment. <i>Value in Health</i> , 2008, 11, 1110-1119.	0.3	48
97	Particle therapy in lung cancer: Where do we stand?. <i>Cancer Treatment Reviews</i> , 2008, 34, 259-267.	7.7	22
98	Patient Preferences for Direct Hearing Aid Provision by a Private Dispenser. A Discrete Choice Experiment. <i>Ear and Hearing</i> , 2008, 29, 557-564.	2.1	10
99	Potential barriers and facilitators for implementation of an integrated care pathway for hearing-impaired persons: an exploratory survey among patients and professionals. <i>BMC Health Services Research</i> , 2007, 7, 57.	2.2	8
100	Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints. <i>Quality of Life Research</i> , 2007, 16, 1439-1449.	3.1	88
101	VV7 WILLINGNESS TO PAY FOR HEARING AIDS IN THE NETHERLANDS. <i>Value in Health</i> , 2003, 6, 612.	0.3	0